

APPENDIX A: CLAIMS NOW PENDING IN THIS APPLICATION

32. (Amended) A method of diagnosing colorectal cancer comprising:
a) determining the expression of a nucleic acid sequence at least 95% identical to SEQ ID NO:1 in a first sample comprising colorectal cancer cells from a first individual; and
(b) comparing the expression of said nucleic acid sequence in the first sample to expression of said nucleic acid sequence in a second sample taken from either normal colon tissue of said first individual or from normal colon tissue, or a bodily secretion of a second unaffected individual;
wherein a difference between the expression in the first sample and the expression in the second sample indicates that the first individual has colorectal cancer.
33. The method of claim 32, wherein said second sample is from said first individual.
34. The method of claim 33, wherein said first sample is colorectal tissue.
35. The method of claim 33, wherein said second sample is colorectal tissue.
36. The method of claim 33, wherein said second sample is cancerous tissue.
37. The method of claim 32, wherein said second sample is from a second individual.

38. The method of claim 37, wherein said first sample is colorectal tissue.
39. The method of claim 37, wherein said second sample is colorectal tissue.
40. The method of claim 37, wherein said second sample is cancerous tissue.
41. The method of claim 32, wherein said gene is SEQ ID NO:1.
42. The method of claim 32, wherein said expression is measured using a labeled nucleic acid probe.
43. The method of claim 32, wherein said expression is measured utilizing a biochip.